Related Experiment Videos
[Current aspects of rheumatoid arthritis]
Fortschritte Der Medizin
|October 25, 1979
Summary
This study found that suxibuzon and indomethacin are equally effective in treating rheumatoid arthritis (R.A.) over four weeks, with no serious side effects. Both nonsteroidal anti-inflammatory drugs offer therapeutic benefits for R.A. patients.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (R.A.) pathogenesis involves genetic factors (HLA-system, familial aggregation) and immune processes causing inflammation and tissue injury.
- Autoimmunity and the immunologic network are critical in R.A. pathogenesis, influencing therapeutic strategies.
- New nonsteroidal anti-inflammatory drugs (NSAIDs) show promise for R.A. treatment.
Purpose of the Study:
- To compare the efficacy and safety of suxibuzon and indomethacin in patients with active rheumatoid arthritis.
- To evaluate clinical and laboratory measurements of disease activity in R.A. patients treated with suxibuzon versus indomethacin.
Main Methods:
- A double-blind study was conducted involving 30 patients diagnosed with active rheumatoid arthritis.
- Patients were treated with either suxibuzon or indomethacin.
- Efficacy was assessed over a 4-week period using clinical and laboratory parameters.
Main Results:
- Both suxibuzon and indomethacin demonstrated significant activity in treating active rheumatoid arthritis.
- The efficacy of suxibuzon and indomethacin was comparable at the 4-week mark.
- No serious toxic side effects were reported for either treatment regimen.
Conclusions:
- Suxibuzon and indomethacin are effective NSAIDs for managing active rheumatoid arthritis.
- Both drugs present a similar efficacy profile and a favorable safety profile for R.A. treatment.
- The findings support the use of these NSAIDs in the therapeutic management of rheumatoid arthritis.